BD Partners With U.S. Government in $19 Billion Manufacturing Push

PR Newswire··Read original
0▲0 ▼0Impact / 5
Summary · why it matters

BD announced a landmark partnership with the U.S. Government to expand domestic manufacturing of essential medical consumables and strengthen healthcare supply chain resilience. Under the agreement, BD intends to invest $19 billion in the U.S. over several years, with $3 billion of that total directed toward U.S. manufacturing expansion at strategic production sites across the country. The company plans to expand end-to-end U.S. production by approximately 5 billion essential medical consumables annually, raising its share of domestically supplied essential medical consumables to roughly 80 percent, and to manufacture 100 percent of BD needles used in America domestically using American-made steel. The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to final scope and implementation and BD's achievement of agreed milestones; because final tariff rates, product scope and timing are undetermined, BD is not currently quantifying the financial impact. BD, described as the nation's largest manufacturer of essential medical consumables, said the products involved are used in approximately 90 percent of U.S. hospital visits, and its U.S. manufacturing network includes sites in Columbus and Broken Bow, NE; Canaan, CT; Añasco, PR; Sandy, UT; El Paso, TX; Covington, GA; and Sumter, SC.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketIVNews